The total surgical robotics market is forecast to generate $10.3bn in 2030, according to GlobalData. Credit: Dana Neely via Getty Images.

Medical Microinstruments (MMI) has announced the completion of its first two clinical cases in the US using the FDA-approved Symani Surgical System. 

The first two US procedures were reconstructive extremity microsurgeries conducted at Penn Medicine, Penn Presbyterian Medical Center. Surgeons performed a “free bone transfer” procedure on a patient who suffered a traumatic injury and to repair a severe knee wound using muscle and skin from the back. Both cases used robotic assistance from Symani for blood vessel reconnection.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The system facilitates microsurgery and super-microsurgery by mimicking human hand movements.  

Symani has already been used more than 500 times in the EU, winning CE clearance, and announcing the launch and first human use in Europe in October 2020. The first four successful robotic surgeries using the system were performed in Florence, Italy. 

It’s been a big year for MMI and the Symani system. In January 2024, MMI teamed up with Italian medical technology production and distribution company ab medica to expand the commercialisation of Symani across the globe. This follows on from two distribution agreements signed by the company in October 2023 – with Device Technologies and TRM Korea – covering 11 countries in the Asia Pacific (APAC) region. 

In February, the company secured $110m in a Series C funding round from investors Fidelity Management & Research Company, to support the commercialisation of the system. Symani then won US Food and Drug Administration (FDA) approval for soft tissue manipulation in microsurgery, a technique involving intricate vessel reconnection to restore blood flow or redirect fluids during reconstruction or repair in April. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to a report on GlobalData’s Medical Intelligence Center, the total surgical robotics market was worth $4.6bn in 2020 globally. By 2030, it will have grown at a compound annual growth rate (CAGR) of 8.5% to $10.3bn. 

GlobalData is the parent company of Clinical Trials Arena.

MMI’s CEO Mark Toland said: “Today marks the beginning of a new era in surgical innovation, as patients across the country with conditions that require complex microsurgical techniques, such as extremity reconstruction, autologous breast reconstruction post-cancer resection and lymphedema repair, will now have expanded access to treatment options.”